Pharmaceutical

EC conditionally approves Pfizer’s haemophilia B gene therapy

The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment.

Jul 28, 2024 - 04:00
EC conditionally approves Pfizer’s haemophilia B gene therapy
The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment.
Read the original article

Tags:

Previous Article

AbbVie’s Q2 2024 net earnings drop to $1.37bn

Next Article

Pfizer’s Hemophilia Gene Treatment Reaches Late-Stage Research Target

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Doctor vs. ChatGPT showed promise and blind spots of generative AI

Doctor vs. ChatGPT showed promise and blind spots of ge...

Oct 20, 2023

STAT+: Truvian presents data for its desktop blood-testing device in a field still in Theranos’s shadow

STAT+: Truvian presents data for its desktop blood-test...

Jul 26, 2023

STAT+: At Orexo, a ‘turning point’ for everything but digital health

STAT+: At Orexo, a ‘turning point’ for everything but d...

Jul 18, 2023